SlideShare a Scribd company logo
1 of 26
Discovery of Epigenetic Chemical Probes Peter J. Brown Project Manager, Epigenetics Nov 19 th  2009 SGC Oxford SGC Toronto SGC Stockholm
Outline ,[object Object],[object Object],[object Object],[object Object]
What is a chemical probe? ,[object Object],[object Object],[object Object]
Why do we need chemical probes? ,[object Object],[object Object],[object Object],[object Object],Public Data from Center of Drug Evaluation and Research: www.fda.gov/cder/ 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 13 12 10 18 9 16 19 9 7 7 9 17 13 6 7 7 0 20 40 60 80 100 120 Yearly FDA Approvals New Drug Approvals New Chemical Entities Priority Reviewed NCEs
Open Access Chemical Probes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Histone DNA Lysine Modification Write Read Erase Acetyl (Ac) HAT Bromo HDAC Methyl (Me n ) HMT Royal KDM Chemical Biology of Epigenetics
Structural Genomics Consortium Epigenetics Project ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Epigenetics Partners (Toronto) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Discovery Strategies ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
HMT Assays in production Struc solved by SGC Struc solved by others Assay in Production BIX-01294
HAT Assays in production Struc solved by SGC Struc solved by others Assay in Production
Assessing HMT Activity Evys Collazo & Raymond C. Trievel et al. (2005) Analytical Biochemistry 342: 86–92
Progress on EHMT2 (G9a) 2007 : first publication: discovered by HTS – mild cell activity at 4 µM ( Mol Cell . 2007;25(3):473-81) 2008 : available from Sigma 2009 : co-crystal structure with GLP ( Nat Struct Mol Biol . 2009 ), using SGC clone and protocol. ,[object Object],[object Object],BIX-01294
Design of UNC0224 as a Potent G9a Inhibitor   BIX-01294 G9a (Thioglo): IC 50  = 0.11   M GLP (Thioglo): IC 50  = 0.062   M Feng Liu & Xin Chen, CICBDD Abdellah Allali-Hassani, SGC UNC0123 G9a (Thioglo): IC 50  = 0.33   M Reduced MW and lipophilicity while maintaining potency Array-based optimization GLP-BIX-01294 complex Adapted from Chang, et al. 2009,  Nat. Stru. Mol. Bio., (16), 316 UNC0224 G9a (Thioglo):  IC 50  = 0.015   M GLP: IC 50  = 0.020   M, inactive vs SETD7 & SETD8 Selective over a panel of 30 non-Epi targets (except hitting M 2  at 82% inh at 1   M)
UNC0224 is a Potent G9a inhibitor BIX-01294  IC50 = 106 nM  UNC0224  IC50 =  15 nM
Binding Studies ITC was performed in duplicate with average K d  values of 130 ± 18 and 23 ± 8 nM for BIX-01294 and UNC0224 respectively. BIX-01294 UNC0224 0.0 0.5 1.0 1.5 -14 -12 -10 -8 -6 -4 -2 0 2 -0.8 -0.6 -0.4 -0.2 0.0 -10 0 10 20 30 40 50 60 70 80 Time (min) µcal/sec Molar Ratio kcal/mole of injectant 0.0 0.5 1.0 1.5 -14 -12 -10 -8 -6 -4 -2 0 2 -0.8 -0.6 -0.4 -0.2 0.0 -10 0 10 20 30 40 50 60 70 80 Time (min) µcal/sec Molar Ratio kcal/mole of injectant 0.0 0.5 1.0 1.5 -8 -6 -4 -2 0 -0.5 -0.4 -0.3 -0.2 -0.1 0.0 -10 0 10 20 30 40 50 60 70 80 Time (min) µcal/sec Molar Ratio kcal/mole of injectant 0.0 0.5 1.0 1.5 -8 -6 -4 -2 0 -0.5 -0.4 -0.3 -0.2 -0.1 0.0 -10 0 10 20 30 40 50 60 70 80 Time (min) µcal/sec Molar Ratio kcal/mole of injectant
Co-crystallization of G9a and UNC0224 Crystals diffracted to better than 1.7Å Deposited in PDB (3K5K)
BIX-01294 co-crystallized with GLP [3fpd] UNC0224 co-crystallized with G9a [3k5k] H3K9me2 co-crystallized with GLP [2rfi]
What are Bromodomains? ,[object Object],[object Object],[object Object],[object Object]
Bromodomain Goals ,[object Object],[object Object],[object Object],[object Object]
Tm shift data for Bromodomains ,[object Object],[object Object],[object Object],[object Object],Thermal stability (DSF)  Bromo Subfamily 1 2 3 5 6 7 8 9 13 14 Bromodomain SMARCA2 LOC93349 BAZ2B ATAD2 BRD9 BRPF1 CREBBP BRD2 BRD4 CECR2 PCAF FALZ Most potent hit  Tm /  ˚C   5.6 12.9 3.0 3.8 5.6 12.1 6.7 4.8 8.4 3.6  5.3 3.9
Temperature A Potent BRD4 Ligand  Tm=7˚C ,[object Object],[object Object],K D  16.20 ± 0.4 nM
Selectivity for the BET subfamily ,[object Object]
BDGBJ000086 selectively displaces  H4KAc 4  from BRD2 ,[object Object],Compound Bromodomain Tm shift / °C Kd (ITC) / nM Alphascreen IC 50  / nM BDGBJ000086 BRD2_1 4.2 70 <41 CREBBP 0.8 16200 7500 BAZ2B 0 nd 202000
Summary ,[object Object],[object Object],[object Object],[object Object]
Acknowledgements ,[object Object],[object Object],[object Object],[object Object],[object Object],Anton Simeonov Oxford Chas Bountra Tom Heightman Stefan Knapp Brian Marsden Stephen Frye Bill Janzen Jian Jin Tim Willson Ryan Trump

More Related Content

What's hot

mpd_poster_final rev2
mpd_poster_final rev2mpd_poster_final rev2
mpd_poster_final rev2
Jade King
 
Protein microarrays, ICAT, and HPLC protein purification
Protein microarrays, ICAT, and HPLC protein purificationProtein microarrays, ICAT, and HPLC protein purification
Protein microarrays, ICAT, and HPLC protein purification
Raul Soto
 
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1
Ben Leong
 

What's hot (19)

Magnetic-bead-coatings-today-and-tomorrow
Magnetic-bead-coatings-today-and-tomorrowMagnetic-bead-coatings-today-and-tomorrow
Magnetic-bead-coatings-today-and-tomorrow
 
Anteo AMG Coupling Kit Overview
Anteo AMG Coupling Kit OverviewAnteo AMG Coupling Kit Overview
Anteo AMG Coupling Kit Overview
 
Technology used for High Level Expression and Purification of Recombinant Pro...
Technology used for High Level Expression and Purification of Recombinant Pro...Technology used for High Level Expression and Purification of Recombinant Pro...
Technology used for High Level Expression and Purification of Recombinant Pro...
 
Excipient combinations to manage protein viscosity for highly concentrated fo...
Excipient combinations to manage protein viscosity for highly concentrated fo...Excipient combinations to manage protein viscosity for highly concentrated fo...
Excipient combinations to manage protein viscosity for highly concentrated fo...
 
LakePharma General Technical Overview
LakePharma General Technical OverviewLakePharma General Technical Overview
LakePharma General Technical Overview
 
Assessment of Embryotoxicity of Compounds in Cosmetics by the Embryonic Stem ...
Assessment of Embryotoxicity of Compounds in Cosmetics by the Embryonic Stem ...Assessment of Embryotoxicity of Compounds in Cosmetics by the Embryonic Stem ...
Assessment of Embryotoxicity of Compounds in Cosmetics by the Embryonic Stem ...
 
Polysaccharide based nanoparticles for encapsualtion and release of antineopl...
Polysaccharide based nanoparticles for encapsualtion and release of antineopl...Polysaccharide based nanoparticles for encapsualtion and release of antineopl...
Polysaccharide based nanoparticles for encapsualtion and release of antineopl...
 
Polymeric nanoparticles for encapsulation and controlled release of bioactive...
Polymeric nanoparticles for encapsulation and controlled release of bioactive...Polymeric nanoparticles for encapsulation and controlled release of bioactive...
Polymeric nanoparticles for encapsulation and controlled release of bioactive...
 
His Tag Protein Production and Purification
His Tag Protein Production and PurificationHis Tag Protein Production and Purification
His Tag Protein Production and Purification
 
Holland Lab/ American Red Cross 07 b
Holland Lab/ American Red Cross 07 bHolland Lab/ American Red Cross 07 b
Holland Lab/ American Red Cross 07 b
 
Characterization of intact antibodies by pre-fractionation using gel electrop...
Characterization of intact antibodies by pre-fractionation using gel electrop...Characterization of intact antibodies by pre-fractionation using gel electrop...
Characterization of intact antibodies by pre-fractionation using gel electrop...
 
mpd_poster_final rev2
mpd_poster_final rev2mpd_poster_final rev2
mpd_poster_final rev2
 
Protein microarrays, ICAT, and HPLC protein purification
Protein microarrays, ICAT, and HPLC protein purificationProtein microarrays, ICAT, and HPLC protein purification
Protein microarrays, ICAT, and HPLC protein purification
 
Dr. Jesús Jiménez Barbero - Simposio Internacional 'Química: respuestas para ...
Dr. Jesús Jiménez Barbero - Simposio Internacional 'Química: respuestas para ...Dr. Jesús Jiménez Barbero - Simposio Internacional 'Química: respuestas para ...
Dr. Jesús Jiménez Barbero - Simposio Internacional 'Química: respuestas para ...
 
The new trends of maldi ms in protein-protein interaction
The new trends of maldi ms in protein-protein interactionThe new trends of maldi ms in protein-protein interaction
The new trends of maldi ms in protein-protein interaction
 
ratanna paper
ratanna paperratanna paper
ratanna paper
 
Shape Signatures Light
Shape Signatures LightShape Signatures Light
Shape Signatures Light
 
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1
 
GLB NF KIR
GLB NF KIRGLB NF KIR
GLB NF KIR
 

Viewers also liked

Viewers also liked (16)

NIH Drug Discovery and Development - NCTT and CTSAs
NIH Drug Discovery and Development - NCTT and CTSAsNIH Drug Discovery and Development - NCTT and CTSAs
NIH Drug Discovery and Development - NCTT and CTSAs
 
Medicinal Chemistry Due Diligence: Computational Predictions of an expert’s e...
Medicinal Chemistry Due Diligence: Computational Predictions of an expert’s e...Medicinal Chemistry Due Diligence: Computational Predictions of an expert’s e...
Medicinal Chemistry Due Diligence: Computational Predictions of an expert’s e...
 
Osp2 sept 2015 OSM/TB
Osp2 sept 2015 OSM/TBOsp2 sept 2015 OSM/TB
Osp2 sept 2015 OSM/TB
 
Identification of Novel STAT3 Target Genes Associated with Oncogenesis
Identification of Novel STAT3 Target Genes Associated with OncogenesisIdentification of Novel STAT3 Target Genes Associated with Oncogenesis
Identification of Novel STAT3 Target Genes Associated with Oncogenesis
 
Combinational Use Of Photoaffinity Label (Iii) &amp; Affinity Column For Off...
Combinational Use Of  Photoaffinity Label (Iii) &amp; Affinity Column For Off...Combinational Use Of  Photoaffinity Label (Iii) &amp; Affinity Column For Off...
Combinational Use Of Photoaffinity Label (Iii) &amp; Affinity Column For Off...
 
tarGET iD
tarGET iDtarGET iD
tarGET iD
 
Lipinski embo chemical biology heidelberg 2014
Lipinski embo chemical biology heidelberg 2014Lipinski embo chemical biology heidelberg 2014
Lipinski embo chemical biology heidelberg 2014
 
II. Use Of Photoaffinity Label For Off Target Id P39
II. Use Of Photoaffinity Label For Off Target Id   P39II. Use Of Photoaffinity Label For Off Target Id   P39
II. Use Of Photoaffinity Label For Off Target Id P39
 
I. Henderson, J. Ingram, D. Poulcharidis - Advanced Topics in Chemical Biolog...
I. Henderson, J. Ingram, D. Poulcharidis - Advanced Topics in Chemical Biolog...I. Henderson, J. Ingram, D. Poulcharidis - Advanced Topics in Chemical Biolog...
I. Henderson, J. Ingram, D. Poulcharidis - Advanced Topics in Chemical Biolog...
 
Probe Sonication
Probe SonicationProbe Sonication
Probe Sonication
 
Optical Imaging Probe development
Optical Imaging Probe developmentOptical Imaging Probe development
Optical Imaging Probe development
 
Drug Discovery - The Origin of New Chemical Entity Pharmaceuticals
Drug Discovery - The Origin of New Chemical Entity PharmaceuticalsDrug Discovery - The Origin of New Chemical Entity Pharmaceuticals
Drug Discovery - The Origin of New Chemical Entity Pharmaceuticals
 
Qsar
QsarQsar
Qsar
 
Nanotechnology Based Drug Delivery
Nanotechnology Based Drug DeliveryNanotechnology Based Drug Delivery
Nanotechnology Based Drug Delivery
 
Drug Design:Discovery, Development and Delivery
Drug Design:Discovery, Development and DeliveryDrug Design:Discovery, Development and Delivery
Drug Design:Discovery, Development and Delivery
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 

Similar to Pjb Probes 2009

Developing DNA topoisomerases as targets for antibacterial chemotherapy
Developing DNA topoisomerases as targets for antibacterial chemotherapyDeveloping DNA topoisomerases as targets for antibacterial chemotherapy
Developing DNA topoisomerases as targets for antibacterial chemotherapy
warwick_amr
 
SF and PE CTR-IN 2016 Poster_FInal
SF and PE CTR-IN 2016 Poster_FInalSF and PE CTR-IN 2016 Poster_FInal
SF and PE CTR-IN 2016 Poster_FInal
Steve Flynn
 
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
AvactaLifeSciences
 
Oncodesign aacr 2018 development of a high throughput in vitro screening pl...
Oncodesign aacr 2018   development of a high throughput in vitro screening pl...Oncodesign aacr 2018   development of a high throughput in vitro screening pl...
Oncodesign aacr 2018 development of a high throughput in vitro screening pl...
Florence Fombertasse
 

Similar to Pjb Probes 2009 (20)

Developing DNA topoisomerases as targets for antibacterial chemotherapy
Developing DNA topoisomerases as targets for antibacterial chemotherapyDeveloping DNA topoisomerases as targets for antibacterial chemotherapy
Developing DNA topoisomerases as targets for antibacterial chemotherapy
 
Monoclonal antibodies,Production + bioseperartion
Monoclonal antibodies,Production + bioseperartionMonoclonal antibodies,Production + bioseperartion
Monoclonal antibodies,Production + bioseperartion
 
RAD51 Drug Discovery (ACS Denver 2011)
RAD51 Drug Discovery (ACS Denver 2011)RAD51 Drug Discovery (ACS Denver 2011)
RAD51 Drug Discovery (ACS Denver 2011)
 
Multi-domain Challenges of Fc Fusion Proteins and Bispecific Antibodies
Multi-domain Challenges of Fc Fusion Proteins and Bispecific AntibodiesMulti-domain Challenges of Fc Fusion Proteins and Bispecific Antibodies
Multi-domain Challenges of Fc Fusion Proteins and Bispecific Antibodies
 
MDC Connects: Hit ID screening - understanding your target is key
MDC Connects: Hit ID screening - understanding your target is keyMDC Connects: Hit ID screening - understanding your target is key
MDC Connects: Hit ID screening - understanding your target is key
 
defense 2.0
defense 2.0defense 2.0
defense 2.0
 
IRJET - Factorial Optimization and Peri-Kinetics of Pharmaceutical Effluent C...
IRJET - Factorial Optimization and Peri-Kinetics of Pharmaceutical Effluent C...IRJET - Factorial Optimization and Peri-Kinetics of Pharmaceutical Effluent C...
IRJET - Factorial Optimization and Peri-Kinetics of Pharmaceutical Effluent C...
 
JBEI Research Highlights - April 2017
JBEI Research Highlights - April 2017JBEI Research Highlights - April 2017
JBEI Research Highlights - April 2017
 
Novel composite electrodes:Preparation and application to the electroanalytic...
Novel composite electrodes:Preparation and application to the electroanalytic...Novel composite electrodes:Preparation and application to the electroanalytic...
Novel composite electrodes:Preparation and application to the electroanalytic...
 
Particles in the Biotech Product Life Cycle: Analysis, Identification and Con...
Particles in the Biotech Product Life Cycle: Analysis, Identification and Con...Particles in the Biotech Product Life Cycle: Analysis, Identification and Con...
Particles in the Biotech Product Life Cycle: Analysis, Identification and Con...
 
Molecular docking MAPK.pptx
Molecular docking MAPK.pptxMolecular docking MAPK.pptx
Molecular docking MAPK.pptx
 
Differential metabolic activity and discovery of therapeutic targets using su...
Differential metabolic activity and discovery of therapeutic targets using su...Differential metabolic activity and discovery of therapeutic targets using su...
Differential metabolic activity and discovery of therapeutic targets using su...
 
Crimson Publishers- CPG Methylation in G-Quadruplex and IMotif DNA Structures
Crimson Publishers- CPG Methylation in G-Quadruplex and IMotif DNA StructuresCrimson Publishers- CPG Methylation in G-Quadruplex and IMotif DNA Structures
Crimson Publishers- CPG Methylation in G-Quadruplex and IMotif DNA Structures
 
Using Calorimetric Data to Drive Accuracy in Computer-Aided Drug Design
Using Calorimetric Data to Drive Accuracy in Computer-Aided Drug DesignUsing Calorimetric Data to Drive Accuracy in Computer-Aided Drug Design
Using Calorimetric Data to Drive Accuracy in Computer-Aided Drug Design
 
Structural Studies of Human GBE1 and Relevance to APBD
Structural Studies of Human GBE1 and Relevance to APBDStructural Studies of Human GBE1 and Relevance to APBD
Structural Studies of Human GBE1 and Relevance to APBD
 
Aptamer as therapeutic
Aptamer as therapeuticAptamer as therapeutic
Aptamer as therapeutic
 
SF and PE CTR-IN 2016 Poster_FInal
SF and PE CTR-IN 2016 Poster_FInalSF and PE CTR-IN 2016 Poster_FInal
SF and PE CTR-IN 2016 Poster_FInal
 
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
 
Design of fragment screening libraries (IQPC 2008)
Design of fragment screening libraries (IQPC 2008)Design of fragment screening libraries (IQPC 2008)
Design of fragment screening libraries (IQPC 2008)
 
Oncodesign aacr 2018 development of a high throughput in vitro screening pl...
Oncodesign aacr 2018   development of a high throughput in vitro screening pl...Oncodesign aacr 2018   development of a high throughput in vitro screening pl...
Oncodesign aacr 2018 development of a high throughput in vitro screening pl...
 

Pjb Probes 2009

  • 1. Discovery of Epigenetic Chemical Probes Peter J. Brown Project Manager, Epigenetics Nov 19 th 2009 SGC Oxford SGC Toronto SGC Stockholm
  • 2.
  • 3.
  • 4.
  • 5.
  • 6. Histone DNA Lysine Modification Write Read Erase Acetyl (Ac) HAT Bromo HDAC Methyl (Me n ) HMT Royal KDM Chemical Biology of Epigenetics
  • 7.
  • 8.
  • 9.
  • 10. HMT Assays in production Struc solved by SGC Struc solved by others Assay in Production BIX-01294
  • 11. HAT Assays in production Struc solved by SGC Struc solved by others Assay in Production
  • 12. Assessing HMT Activity Evys Collazo & Raymond C. Trievel et al. (2005) Analytical Biochemistry 342: 86–92
  • 13.
  • 14. Design of UNC0224 as a Potent G9a Inhibitor BIX-01294 G9a (Thioglo): IC 50 = 0.11  M GLP (Thioglo): IC 50 = 0.062  M Feng Liu & Xin Chen, CICBDD Abdellah Allali-Hassani, SGC UNC0123 G9a (Thioglo): IC 50 = 0.33  M Reduced MW and lipophilicity while maintaining potency Array-based optimization GLP-BIX-01294 complex Adapted from Chang, et al. 2009, Nat. Stru. Mol. Bio., (16), 316 UNC0224 G9a (Thioglo): IC 50 = 0.015  M GLP: IC 50 = 0.020  M, inactive vs SETD7 & SETD8 Selective over a panel of 30 non-Epi targets (except hitting M 2 at 82% inh at 1  M)
  • 15. UNC0224 is a Potent G9a inhibitor BIX-01294 IC50 = 106 nM UNC0224 IC50 = 15 nM
  • 16. Binding Studies ITC was performed in duplicate with average K d values of 130 ± 18 and 23 ± 8 nM for BIX-01294 and UNC0224 respectively. BIX-01294 UNC0224 0.0 0.5 1.0 1.5 -14 -12 -10 -8 -6 -4 -2 0 2 -0.8 -0.6 -0.4 -0.2 0.0 -10 0 10 20 30 40 50 60 70 80 Time (min) µcal/sec Molar Ratio kcal/mole of injectant 0.0 0.5 1.0 1.5 -14 -12 -10 -8 -6 -4 -2 0 2 -0.8 -0.6 -0.4 -0.2 0.0 -10 0 10 20 30 40 50 60 70 80 Time (min) µcal/sec Molar Ratio kcal/mole of injectant 0.0 0.5 1.0 1.5 -8 -6 -4 -2 0 -0.5 -0.4 -0.3 -0.2 -0.1 0.0 -10 0 10 20 30 40 50 60 70 80 Time (min) µcal/sec Molar Ratio kcal/mole of injectant 0.0 0.5 1.0 1.5 -8 -6 -4 -2 0 -0.5 -0.4 -0.3 -0.2 -0.1 0.0 -10 0 10 20 30 40 50 60 70 80 Time (min) µcal/sec Molar Ratio kcal/mole of injectant
  • 17. Co-crystallization of G9a and UNC0224 Crystals diffracted to better than 1.7Å Deposited in PDB (3K5K)
  • 18. BIX-01294 co-crystallized with GLP [3fpd] UNC0224 co-crystallized with G9a [3k5k] H3K9me2 co-crystallized with GLP [2rfi]
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.